LIGAND PHARMACEUTICALS INCORPORATED has a total of 53 patent applications. It increased the IP activity by 66.0%. Its first patent ever was published in 1994. It filed its patents most often in Australia, United States and Argentina. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and environmental technology are Grünenthal GmbH , KISSEI FARMAS JUTIKAL KO LTD and CIRIUS THERAPEUTICS INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 17 | |
#2 | United States | 17 | |
#3 | Argentina | 3 | |
#4 | Mexico | 3 | |
#5 | Brazil | 2 | |
#6 | China | 2 | |
#7 | Japan | 2 | |
#8 | Republic of Korea | 2 | |
#9 | Canada | 1 | |
#10 | Chile | 1 | |
#11 | EPO (European Patent Office) | 1 | |
#12 | Taiwan | 1 | |
#13 | WIPO (World Intellectual Property Organization) | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Environmental technology | |
#4 | Biotechnology | |
#5 | Medical technology |
# | Name | Total Patents |
---|---|---|
#1 | Zhi Lin | 35 |
#2 | Shen Yixing | 12 |
#3 | Pedram Bijan | 11 |
#4 | Pickens Jason C | 10 |
#5 | Rosen David | 9 |
#6 | Van Oeveren Cornelis A | 8 |
#7 | Ho Koc-Kan | 8 |
#8 | Letourneau Jeffrey J | 7 |
#9 | Mcguinness Brian F | 7 |
#10 | Cole Andrew G | 7 |
Publication | Filing date | Title |
---|---|---|
CN111954560A | Glucagon receptor antagonists | |
AU2004200443A1 | Dimer-selective RXR modulators and methods for their use | |
AU2003248406A1 | Steroid receptor modulator compounds and methods | |
AU6941200A | 8-substituted-6-trifluoromethyl-9-pyrido(3,2-g)quinoline compounds as androgen receptor modulators | |
AU1732900A | Methods of treating thrombocytopenia | |
AU9713798A | DNA spacer regulatory elements responsive to cytokines and methods for their use | |
AU2603095A | Methods for the synthesis of 9-(cis) retinoids and their novel intermediates | |
AU2285995A | Dna spacer regulatory elements responsive to cytokines and methods for their use |